SNOMED CT, US Edition

Last uploaded: March 22, 2026
Id http://purl.bioontology.org/ontology/SNOMEDCT/363231009
http://purl.bioontology.org/ontology/SNOMEDCT/363231009
Preferred Name

Neoplastic complication of procedure
Synonyms
Neoplastic complication of procedure (disorder)
Type http://www.w3.org/2002/07/owl#Class

All Properties

prefLabel
Neoplastic complication of procedure
altLabel
Neoplastic complication of procedure (disorder)
Type ID
900000000000003001
900000000000013009
Semantic type UMLS property
Occurs after
Effective time
20220228
cui
C1285376
CTV3ID
XUPlj
DEFINITION STATUS ID
900000000000073002
CASE SIGNIFICANCE ID
900000000000448009
tui
T046
Active
1
Has associated morphology
notation
363231009
type
subClassOf
Due to
Subset member
6011000124106~MAPTARGET~T81.89X?
6011000124106~MAPADVICE~IF PUVA THERAPY-ASSOCIATED SKIN MALIGNANCY CHOOSE C44.90 | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPADVICE~IF PUVA THERAPY-ASSOCIATED MALIGNANT MELANOMA CHOOSE Y84.2 | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPTARGET~C44.92
6011000124106~MAPTARGET~Y84.2
6011000124106~MAPADVICE~IF PUVA THERAPY-ASSOCIATED MALIGNANT MELANOMA CHOOSE C43.9 | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPTARGET~C92.00
447562003~MAPRULE~TRUE
6011000124106~MAPADVICE~ALWAYS D49.9 | DESCENDANTS NOT EXHAUSTIVELY MAPPED
6011000124106~MAPADVICE~IF PUVA THERAPY-ASSOCIATED SQUAMOUS CELL CARCINOMA CHOOSE C44.92 | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPADVICE~IF PUVA THERAPY-ASSOCIATED SKIN MALIGNANCY CHOOSE T65.891? | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | EPISODE OF CARE INFORMATION NEEDED | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPPRIORITY~7
6011000124106~MAPPRIORITY~4
6011000124106~MAPRULE~IFA 762315004 | Therapy related acute myeloid leukemia due to and following administration of antineoplastic agent |
6011000124106~MAPADVICE~MAP SOURCE CONCEPT CANNOT BE CLASSIFIED WITH AVAILABLE DATA
6011000124106~MAPTARGET~
6011000124106~MAPCATEGORYID~447638001
6011000124106~MAPADVICE~IF VACCINE-INDUCED FIBROSARCOMA CHOOSE C49.9 | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPTARGET~T65.891?
6011000124106~MAPGROUP~1
6011000124106~MAPGROUP~2
6011000124106~MAPADVICE~IF VACCINE-INDUCED FIBROSARCOMA CHOOSE T88.1XX? | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | EPISODE OF CARE INFORMATION NEEDED | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT | POSSIBLE REQUIREMENT FOR AN EXTERNAL CAUSE CODE
6011000124106~MAPRULE~IFA 403712008 | PUVA therapy-associated basal cell carcinoma |
6011000124106~MAPADVICE~IF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME RELATED TO ALKYLATING AGENT CHOOSE T45.1X5S | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPTARGET~C43.9
6011000124106~MAPPRIORITY~10
447562003~MAPADVICE~MAP SOURCE CONCEPT CANNOT BE CLASSIFIED WITH AVAILABLE DATA
6011000124106~MAPADVICE~IF THERAPY RELATED ACUTE MYELOID LEUKEMIA DUE TO AND FOLLOWING ADMINISTRATION OF ANTINEOPLASTIC AGENT CHOOSE T45.1X5? | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | EPISODE OF CARE INFORMATION NEEDED | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPPRIORITY~8
6011000124106~MAPRULE~IFA 403714009 | PUVA therapy-associated malignant melanoma |
6011000124106~MAPADVICE~IF PUVA THERAPY-ASSOCIATED BASAL CELL CARCINOMA CHOOSE C44.91 | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPADVICE~IF PUVA THERAPY-ASSOCIATED SKIN MALIGNANCY CHOOSE Y84.2 | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPADVICE~ALWAYS T81.89X? | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | DESCENDANTS NOT EXHAUSTIVELY MAPPED | EPISODE OF CARE INFORMATION NEEDED | POSSIBLE REQUIREMENT FOR AN EXTERNAL CAUSE CODE
6011000124106~MAPRULE~IFA 766045006 | Acute myeloid leukemia and myelodysplastic syndrome related to alkylating agent |
447562003~MAPGROUP~1
6011000124106~MAPRULE~IFA 403713003 | PUVA therapy-associated squamous cell carcinoma |
447562003~CORRELATIONID~447561005
6011000124106~MAPCATEGORYID~447637006
6011000124106~MAPTARGET~T45.1X5?
6011000124106~MAPTARGET~C92.40
6011000124106~MAPADVICE~IF PUVA THERAPY-ASSOCIATED BASAL CELL CARCINOMA CHOOSE Y84.2 | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
900000000000509007~ACCEPTABILITYID~900000000000548007
6011000124106~MAPADVICE~IF PUVA THERAPY-ASSOCIATED SQUAMOUS CELL CARCINOMA CHOOSE Y84.2 | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPADVICE~IF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME RELATED TO ALKYLATING AGENT CHOOSE D46.9 | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
900000000000508004~ACCEPTABILITYID~900000000000548007
447562003~MAPTARGET~
6011000124106~MAPTARGET~T88.1XX?
447562003~MAPPRIORITY~1
6011000124106~MAPRULE~OTHERWISE TRUE
6011000124106~MAPPRIORITY~5
6011000124106~MAPADVICE~IF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME RELATED TO TOPOISOMERASE TYPE 2 INHIBITOR CHOOSE D46.9 | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPTARGET~C49.9
6011000124106~MAPPRIORITY~9
6011000124106~MAPCATEGORYID~447639009
6011000124106~MAPADVICE~IF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME RELATED TO TOPOISOMERASE TYPE 2 INHIBITOR CHOOSE C92.00 | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
900000000000497000~MAPTARGET~XUPlj
6011000124106~MAPTARGET~C92.90
6011000124106~MAPTARGET~C44.90
6011000124106~MAPADVICE~IF DIFFERENTIATION SYNDROME DUE TO AND FOLLOWING CHEMOTHERAPY CO-OCCURRENT WITH ACUTE PROMYELOCYTIC LEUKEMIA CHOOSE C92.40 | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPADVICE~ALWAYS T81.89X? | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | EPISODE OF CARE INFORMATION NEEDED | POSSIBLE REQUIREMENT FOR AN EXTERNAL CAUSE CODE
6011000124106~MAPADVICE~IF THERAPY RELATED ACUTE MYELOID LEUKEMIA DUE TO AND FOLLOWING ADMINISTRATION OF ANTINEOPLASTIC AGENT CHOOSE C92.90 | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPPRIORITY~1
6011000124106~MAPTARGET~C44.91
6011000124106~MAPTARGET~D49.9
6011000124106~MAPTARGET~T45.1X5S
6011000124106~MAPPRIORITY~6
6011000124106~CORRELATIONID~447561005
6011000124106~MAPRULE~IFA 773537001 | Differentiation syndrome due to and following chemotherapy co-occurrent with acute promyelocytic leukemia |
6011000124106~MAPRULE~IFA 403711001 | PUVA therapy-associated skin malignancy |
6011000124106~MAPTARGET~D46.9
6011000124106~MAPRULE~TRUE
6011000124106~MAPGROUP~3
6011000124106~MAPADVICE~ALWAYS D49.9
6011000124106~MAPPRIORITY~3
6011000124106~MAPRULE~IFA 766046007 | Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor |
6011000124106~MAPPRIORITY~2
6011000124106~MAPADVICE~IF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME RELATED TO TOPOISOMERASE TYPE 2 INHIBITOR CHOOSE T45.1X5S | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
447562003~MAPCATEGORYID~447638001
6011000124106~MAPADVICE~IF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME RELATED TO ALKYLATING AGENT CHOOSE C92.00 | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
6011000124106~MAPRULE~IFA 370511006 | Vaccine-induced fibrosarcoma |
6011000124106~MAPADVICE~IF DIFFERENTIATION SYNDROME DUE TO AND FOLLOWING CHEMOTHERAPY CO-OCCURRENT WITH ACUTE PROMYELOCYTIC LEUKEMIA CHOOSE T45.1X5? | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | EPISODE OF CARE INFORMATION NEEDED | MAP OF SOURCE CONCEPT IS CONTEXT DEPENDENT
See more
See less
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display